Addex Partner Janssen Discontinues ADX71149 Epilepsy Treatment After Phase 2 Study
Portfolio Pulse from Benzinga Newsdesk
Addex's partner Janssen has decided to discontinue the development of ADX71149 for epilepsy treatment after a Phase 2 study failed to meet its primary endpoint. The study showed that ADX71149 did not significantly improve seizure control in patients with focal onset seizures.
July 22, 2024 | 6:12 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Janssen, a subsidiary of Johnson & Johnson, has decided to discontinue the development of ADX71149 for epilepsy treatment after a Phase 2 study failed to meet its primary endpoint.
The discontinuation of ADX71149 could negatively impact Johnson & Johnson's stock price in the short term due to the failure of the drug to meet its primary endpoint in the Phase 2 study, which may affect investor sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80